Literature DB >> 26825731

Early induction of labor in high-risk intrahepatic cholestasis of pregnancy: what are the costs?

Anne Katrine Friberg1, Vera Zingmark2, Jens Lyndrup2.   

Abstract

PURPOSE: Induction of labor among pregnant women with high levels of total bile acid (TBA) is common among clinicians. We examined, if women with intrahepatic cholestasis of pregnancy (ICP) and TBA ≥ 40 μmol/l have a higher risk of maternal-fetal complications, when labor is induced at 37 weeks of gestation, compared with induction of labor at term in women with low-risk ICP.
METHODS: Retrospective cohort study of 16,185 women delivering at Roskilde University Hospital in the period 2006-2011. Women with high-risk ICP (TBA ≥ 40 μmol/l) had labor induced at 37 weeks of gestation; women with low-risk ICP (TBA < 40 μmol/l) at term. OUTCOMES: Mode of delivery, duration of induction procedures, highest level of TBA and alanine aminotransferase (ALT) and for the neonates: Apgar scores at 5 min, umbilical cord pHs and SBEs, NICU admissions and birthweights.
RESULTS: The incidences of ICP was 1.2 % (95 % CI 1.05-1.39 %) altogether and for high-risk ICP 0.4 % (95 % CI 0.27-0.46 %). No difference was found in mode of delivery, length of induction of labor nor in neonatal outcomes, except for an expected difference in birthweight. In high-risk ICP, ALT was not raised in 10.3 % (95 % CI 2.5-18.2 %).
CONCLUSION: Early induction of labor at 37 weeks of gestation seems justified in high-risk ICP, as, except for abbreviating gestational age by 9 days with 296 g smaller babies, induction of labor was not followed by detectable maternal-fetal disadvantages and is favored by an expected major reduction in ICP stillbirth risk.

Entities:  

Keywords:  Cesarean section; Induction of labor; Intrahepatic cholestasis of pregnancy; Total bile acid concentration

Mesh:

Substances:

Year:  2016        PMID: 26825731     DOI: 10.1007/s00404-016-4019-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

Review 1.  Immunology of hepatic diseases during pregnancy.

Authors:  Lars Bremer; Christoph Schramm; Gisa Tiegs
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

2.  Placental Abruption and Partial Placental Prolapse During Induction of Labor in a 31-Year-Old Female With Intrahepatic Cholestasis of Pregnancy: A Case Report.

Authors:  Maurice H Dick; Monique Brotman
Journal:  Cureus       Date:  2022-04-09

3.  Can we predict severity of intrahepatic cholestasis of pregnancy using inflammatory markers?

Authors:  Çiğdem Yayla Abide; Fisun Vural; Çetin Kılıççı; Evrim Bostancı Ergen; İlter Yenidede; Ahmet Eser; Oya Pekin
Journal:  Turk J Obstet Gynecol       Date:  2017-09-30

Review 4.  Stillbirth and associated perinatal outcomes in obstetric cholestasis: a systematic review and meta-analysis of observational studies.

Authors:  Manoj Mohan; Antoniou Antonios; Justin Konje; Stephen Lindow; Mohamed Ahmed Syed; Anthony Akobeng
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-02

5.  Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes.

Authors:  Jielian Yang; Chong Chen; Min Liu; Shuye Zhang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Effect of Oxytocin Combined with Different Volume of Water Sac in High-Risk Term Pregnancies.

Authors:  Hanna Mi; Na Sun
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-06       Impact factor: 2.650

7.  Occurrence of Liver Damage and Obstetric Outcomes in Pregnant Women Diagnosed with Pruritus during Pregnancy: A Retrospective Study.

Authors:  Ena Pavelic; Vladimir Blagaic; Paulo Zekan; Petra Glad Stritof; Mara Bebek; Josko Bilandzic; Milan Pavlovic; Mihovil Herceg
Journal:  Int J Clin Pract       Date:  2022-09-14       Impact factor: 3.149

8.  Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid.

Authors:  Maria C Estiú; Maria A Frailuna; Carla Otero; Marcela Dericco; Catherine Williamson; Jose J G Marin; Rocio I R Macias
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.